
Middle East and Africa Biosimulation Market Report and Forecast 2024-2032
Description
Middle East and Africa Biosimulation Market Report and Forecast 2024-2032
Middle East and Africa Biosimulation Market Report and Forecast 2024-2032
Middle East and Africa Biosimulation Market Size
The global biosimulation market was valued at USD 3.5 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising investments in the drug discovery activities. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.
Middle East and Africa Biosimulation Market Outlook
- The market size is influenced by the growing adoption of biosimulation techniques to identify potential drug candidates and expedite the development of safer and more targeted treatments with accurate dosing regimen.
- The market is witnessing multiple investment activities aimed at stimulating the growth of the pharmacometrics sector are expected to boost the Middle East and Africa biosimulation market share. Certara, Inc. invested in the Applied Pharmacometrics Training Fellowship program which started in January 2022 , to train African scientists in pharmacometrics and model-based analyses.
- It is estimated that more than 1 in 4 people are affected by non-communicable diseases in Saudi Arabia. This increasing prevalence of diseases is likely to create more emphasis on the adoption of biosimulation techniques, thereby fuelling the market demand.
Biosimulation utilizes computational models and simulations to determine how drugs work, predict side effects and optimal dosing, and design better treatments for diseases. It leverages mathematical and computational techniques to analyze the dynamics of biological systems and how they will respond under different interventions. This approach is increasingly used to identify potential drug candidates due to its ability to accelerate drug development processes in a cost-effective way. The growing interest in in-silico drug discovery is expected to drive the Middle East and Africa biosimulation market growth.
The rising burden of non-communicable diseases also impacts the market dynamics in the region. Recent data states that cardiovascular diseases, cancer, diabetes , and chronic respiratory diseases (amongst four main non-communicable diseases) are responsible for the death of 22,000 people in Saudi Arabia every year. Further, it is estimated that more than 1 in 4 people are affected by any one of the 4 main non-communicable diseases, reflecting the urgent need for effective therapies. This increasing prevalence of diseases is anticipated to create more emphasis on the adoption of biosimulation techniques in order to expedite the development of safer and more targeted treatments. Consequently, this is poised to fuel the Middle East and Africa biosimulation market demand.
One of the major market trends is the increased investment in the pharmacometrics sector, which is likely to augment the demand for biosimulation software and services in the forecast period. For instance, in January 2022, Certara, Inc., a global leader in biosimulation, invested in the Applied Pharmacometrics Training Fellowship program to train African scientists in pharmacometrics and model-based analyses. This investment initiative by Certara in the fellowship program not only stimulates capacity building in Africa but also paves the way for potential market growth opportunities for the company in the region. Other factors such as the rising number of government-backed grants and research funding programs are also contributing to the market growth.
Middle East and Africa Biosimulation Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
Services
Software
Others
Market Breakup by Application
Drug Development
Drug Discovery
Other Applications
Market Breakup by Delivery Type
Subscription Model
Ownership Model
Others
Market Breakup by End User
Biotechnology and Pharmaceutical Companies
Research Institutes
Contract Research Organizations
Market Breakup by Country
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific INC.
- BIO-RAD Laboratories
- Illumina, INC.
- QIAGEN
- F. Hoffmann-La Roche LTD.
- Revvity
- Pacbio
- Agilent Technologies, INC.
- Sysmex Corporation
- BGI
- Eurofins Scientific SE
FAQs
- What is the Middle East and Africa biosimulation market forecast outlook for 2024-2032?
- What are the major factors aiding the Middle East and Africa biosimulation market demand?
- What are the major Middle East and Africa biosimulation market trends?
- What is the market segmentation based on the product?
- What is the market breakup by delivery model?
- What are the major end users of the market?
- What are the applications of biosimulation?
- What is the market segmentation by countries?
- Who are the key players involved in the Middle East and Africa biosimulation market?
Meta description
The Middle East and Africa biosimulation market is poised for growth, driven by the expansion of the global market, which was valued at USD 3.5 billion in 2023 and is projected to grow at a CAGR of 16.90% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Middle East and Africa Biosimulation Market Overview
- 3.1 Middle East and Africa Biosimulation Market Historical Value (2017-2023)
- 3.2 Middle East and Africa Biosimulation Market Forecast Value (2024-2032)
- 4 Middle East and Africa Biosimulation Market Landscape*
- 4.1 Middle East and Africa Biosimulation: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Middle East and Africa Biosimulation: Product Landscape
- 4.2.1 Analysis by Product
- 4.2.2 Analysis by Delivery Model
- 5 Middle East and Africa Biosimulation Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Middle East and Africa Biosimulation Market Segmentation (2017-2032)
- 6.1 Middle East and Africa Biosimulation Market (2017-2032) by Product
- 6.1.1 Market Overview
- 6.1.2 Software
- 6.1.3 Services
- 6.1.4 Others
- 6.2 Middle East and Africa Biosimulation Market (2017-2032) by Delivery Model
- 6.2.1 Market Overview
- 6.2.2 Subscription Model
- 6.2.3 Ownership Model
- 6.2.4 Others
- 6.3 Middle East and Africa Biosimulation Market (2017-2032) by Application
- 6.3.1 Market Overview
- 6.3.2 Drug Development
- 6.3.3 Drug Discovery
- 6.3.4 Others
- 6.4 Middle East and Africa Biosimulation Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Pharmaceutical and Biotechnology Companies
- 6.4.3 Contract Research Organization
- 6.4.4 Academic and Research Institutes
- 6.5 Middle East and Africa Biosimulation Market (2017-2032) by Countries
- 6.5.1 Market Overview
- 6.5.2 Saudi Arabia
- 6.5.3 United Arab Emirates
- 6.5.4 Nigeria
- 6.5.5 South Africa
- 6.5.6 Others
- 7 Saudi Arabia Biosimulation Market (2017-2032)
- 7.1 Saudi Arabia Biosimulation Market (2017-2032) by Product
- 7.1.1 Market Overview
- 7.1.2 Software
- 7.1.3 Services
- 7.1.4 Others
- 7.2 Saudi Arabia Biosimulation Market (2017-2032) by Delivery Model
- 7.2.1 Market Overview
- 7.2.2 Subscription Model
- 7.2.3 Ownership Model
- 7.2.4 Others
- 7.3 Saudi Arabia Biosimulation Market (2017-2032) by Application
- 7.3.1 Market Overview
- 7.3.2 Drug Development
- 7.3.3 Drug Discovery
- 7.3.4 Others
- 7.4 Saudi Arabia Biosimulation Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Pharmaceutical and Biotechnology Companies
- 7.4.3 Contract Research Organization
- 7.4.4 Academic and Research Institutes
- 8 United Arab Emirates Biosimulation Market (2017-2032)
- 8.1 United Arab Emirates Biosimulation Market (2017-2032) by Product
- 8.1.1 Market Overview
- 8.1.2 Software
- 8.1.3 Services
- 8.1.4 Others
- 8.2 United Arab Emirates Biosimulation Market (2017-2032) by Delivery Model
- 8.2.1 Market Overview
- 8.2.2 Subscription Model
- 8.2.3 Ownership Model
- 8.2.4 Others
- 8.3 United Arab Emirates Biosimulation Market (2017-2032) by Application
- 8.3.1 Market Overview
- 8.3.2 Drug Development
- 8.3.3 Drug Discovery
- 8.3.4 Others
- 8.4 United Arab Emirates Biosimulation Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Pharmaceutical and Biotechnology Companies
- 8.4.3 Contract Research Organization
- 8.4.4 Academic and Research Institutes
- 9 Nigeria Biosimulation Market (2017-2032)
- 9.1 Nigeria Biosimulation Market (2017-2032) by Product
- 9.1.1 Market Overview
- 9.1.2 Software
- 9.1.3 Services
- 9.1.4 Others
- 9.2 Nigeria Biosimulation Market (2017-2032) by Delivery Model
- 9.2.1 Market Overview
- 9.2.2 Subscription Model
- 9.2.3 Ownership Model
- 9.2.4 Others
- 9.3 Nigeria Biosimulation Market (2017-2032) by Application
- 9.3.1 Market Overview
- 9.3.2 Drug Development
- 9.3.3 Drug Discovery
- 9.3.4 Others
- 9.4 Nigeria Biosimulation Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Pharmaceutical and Biotechnology Companies
- 9.4.3 Contract Research Organization
- 9.4.4 Academic and Research Institutes
- 10 South Africa Biosimulation Market (2017-2032)
- 10.1 South Africa Biosimulation Market (2017-2032) by Product
- 10.1.1 Market Overview
- 10.1.2 Software
- 10.1.3 Services
- 10.1.4 Others
- 10.2 South Africa Biosimulation Market (2017-2032) by Delivery Model
- 10.2.1 Market Overview
- 10.2.2 Subscription Model
- 10.2.3 Ownership Model
- 10.2.4 Others
- 10.3 South Africa Biosimulation Market (2017-2032) by Application
- 10.3.1 Market Overview
- 10.3.2 Drug Development
- 10.3.3 Drug Discovery
- 10.3.4 Others
- 10.4 South Africa Biosimulation Market (2017-2032) by End User
- 10.4.1 Market Overview
- 10.4.2 Pharmaceutical and Biotechnology Companies
- 10.4.3 Contract Research Organization
- 10.4.4 Academic and Research Institutes
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Funding and Investment Analysis
- 13.1 Analysis by Funding Instances
- 13.2 Analysis by Type of Funding
- 13.3 Analysis by Funding Amount
- 13.4 Analysis by Leading Players
- 13.5 Analysis by Leading Investors
- 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
- 14.1 Analysis by Partnership Instances
- 14.2 Analysis by Type of Partnership
- 14.3 Analysis by Leading Players
- 14.4 Analysis by Geography
- 15 Supplier Landscape
- 15.1 Market Share by Top 5 Companies
- 15.2 Thermo Fisher Scientific Inc.
- 15.2.1 Financial Analysis
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 BIO-RAD Laboratories
- 15.3.1 Financial Analysis
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 ILLUMINA, INC.
- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 QIAGEN
- 15.5.1 Financial Analysis
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 F. Hoffmann-La Roche LTD.
- 15.6.1 Financial Analysis
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 REVVITY
- 15.7.1 Financial Analysis
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 PACBIO
- 15.8.1 Financial Analysis
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 AGILENT TECHNOLOGIES, INC.
- 15.9.1 Financial Analysis
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 SYSMEX CORPORATION
- 15.10.1 Financial Analysis
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 15.11 BGI
- 15.11.1 Financial Analysis
- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and Acquisitions
- 15.11.5 Certifications
- 15.12 EUROFINS SCIENTIFIC SE
- 15.12.1 Financial Analysis
- 15.12.2 Product Portfolio
- 15.12.3 Demographic Reach and Achievements
- 15.13.4 Mergers and Acquisitions
- 15.14.5 Certifications
- 16 Middle East and Africa Biosimulation Market – Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
- 18.1 Very Small Companies
- 18.2 Small Companies
- 18.3 Mid-Sized Companies
- 18.4 Large Companies
- 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
- 19.1 Government Funded
- 19.2 Private Insurance
- 19.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.